Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

But this doesn't negate the drugs' potential downsides, one of which has doctors urging patients to "proceed with caution" ...

Glucagon-like peptide 1 receptor agonists, which are found in Ozempic-like drugs, can could cause devastating symptoms in ...